JAGUAR HEALTH, INC. SEVERANCE AND CHANGE OF CONTROL AGREEMENTSeverance and Change of Control Agreement • August 13th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations • California
This Severance and Change of Control Agreement (the “Agreement”) is made and entered into by and between (the “Executive”) and Jaguar Health, Inc., a Delaware Corporation (the “Company”), effective as of June 23, 2020 (the “Effective Date”). Certain capitalized terms used in this Agreement are defined in Exhibit A attached hereto
ASSIGNMENT AGREEMENT To FIRST AMENDMENTAssignment Agreement • August 13th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations • New York
THIS ASSIGNMENT AGREEMENT TO FIRST AMENDMENT (this "Agreement"), effective as of June 26, 2020, is entered into by and between NAPO PHARMACEUTICALS, INC., a Delaware corporation ("Assignor"), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company ("Assignee"). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement (as defined below).
FIRST AMENDMENT TO ACCOUNTS RECEIVABLE PURCHASE AGREEMENTAccounts Receivable Purchase Agreement • August 13th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO ACCOUNTS RECEIVABLE PURCHASE AGREEMENT (this “Amendment”), dated as of June 26, 2020, is entered into between JAGUAR HEALTH, INC., a Delaware corporation, NAPO PHARMACEUTICALS, INC., a Delaware corporation (collectively, jointly and severally, “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (“Purchaser”).
